Is Global Blood Therapeutics Inc (GBT)’s Fuel For Real? The Stock Just Increased Again

September 17, 2017 - By reb123z

The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) is a huge mover today! The stock increased 6.06% or $1.6 on September 15, reaching $28. About 1.68M shares traded or 137.89% up from the average. Global Blood Therapeutics Inc (NASDAQ:GBT) has risen 43.51% since September 17, 2016 and is uptrending. It has outperformed by 26.81% the S&P500.
The move comes after 5 months positive chart setup for the $1.22B company. It was reported on Sep, 17 by We have $29.12 PT which if reached, will make NASDAQ:GBT worth $48.80M more.

Analysts await Global Blood Therapeutics Inc (NASDAQ:GBT) to report earnings on November, 8. They expect $-0.61 earnings per share, down 5.17 % or $0.03 from last year’s $-0.58 per share. After $-0.55 actual earnings per share reported by Global Blood Therapeutics Inc for the previous quarter, Wall Street now forecasts 10.91 % negative EPS growth.

Global Blood Therapeutics Inc (NASDAQ:GBT) Ratings Coverage

Among 5 analysts covering Global Blood Therapeutics (NASDAQ:GBT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Global Blood Therapeutics had 8 analyst reports since September 8, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Cowen & Co on Tuesday, September 8. The firm has “Outperform” rating by Wedbush given on Tuesday, September 8. The stock has “Buy” rating by Empire on Friday, June 17. The stock has “Neutral” rating by Goldman Sachs on Tuesday, September 8. The company was maintained on Tuesday, October 25 by Wedbush. The stock of Global Blood Therapeutics Inc (NASDAQ:GBT) has “Overweight” rating given on Tuesday, September 8 by Morgan Stanley. The firm earned “Overweight” rating on Wednesday, January 4 by JP Morgan.

More notable recent Global Blood Therapeutics Inc (NASDAQ:GBT) news were published by: which released: “A Comparison Of Global Blood Therapeutics’ GBT440 And bluebird bio’s LentiGlobin” on April 07, 2017, also with their article: “Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk” published on March 08, 2017, published: “Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual …” on September 06, 2017. More interesting news about Global Blood Therapeutics Inc (NASDAQ:GBT) were released by: and their article: “Global Blood Therapeutics Announces Upcoming Participation in Multiple …” published on March 01, 2017 as well as‘s news article titled: “Global Blood Therapeutics stock surges 5% on eligibility for European priority …” with publication date: June 28, 2017.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.22 billion. The Firm is engaged in discovering, developing and commercializing therapeutics to treat blood disorders. It currently has negative earnings. The Firm is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease .

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.